February 23, 2026 / Sciad Communications / Watchmaker Genomics / At the Advances in Genome Biology and Technology (AGBT) General Meeting 2026 in Orlando, FL, Volta Labs, a leader in next-generation ...
Phase III data show the Braftovi regimen significantly improves overall survival and response versus chemo as a frontline treatment for advanced tumors.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that ...
This study is a valuable contribution that comprehensively identifies and characterizes LC3B-binding peptides through a bacterial cell-surface display screen covering approximately 500,000 human ...